Pure Biologics

Pure Biologics is a biopharmaceutical company focused on the biological drug and non-systemic therapies discovery and development. We operate in the areas of immuno-oncology, autoimmunology, and rare neurological diseases, conducting research based on our own technology platforms for the selection of active molecules – antibodies and aptamers. Pure Biologics also offers commercial partnership options in several areas including early phase biological drug discovery and development, selection and characterisation of antibodies and aptamers, as well as protein production, purification and analysis. The company is implementing a project titled "Development of a bispecific antibody fragment for the simultaneous targeting of cancer and recruitment of immune system cells [PHASE II]", co-financed by the European Funds for the Modern Economy 2021-2027 (FENG) under action 01.01 SMART Pathways – R&D module of the FENG Program. Agreement No. FENG.01.01-IP.01-1008/23-00 dated 26.09.2024. Project cost: 5 848 PLN Funding amount: 2 924 PLN Project Subject: The subject of the project is R&D work in the area of innovative medical solutions and the implementation of innovations at a global level. Project Objective: A phase 0 clinical trial in patients with solid tumors, which will confirm the mechanism of action and, consequently, the anti-cancer activity of PBA-0405 in the complex microenvironment of human tumors. The goal is to demonstrate the efficacy of the drug under development in human tumors in a phase 0 clinical trial. Phase II tasks: Development work, including continuation of stability testing and phase O clinical trials – patient studies. Project implementation period: 01.01.2024 – 15.11.2025 Contact: info@purebiologics.com | inwestor@purebiologics.com | recruitment@purebiologics.com